Navigation Links
Repligen Receives Notice of Allowance for Recombinant Protein A Patent
Date:2/3/2010

WALTHAM, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. The patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities.  This product has been developed as an alternative to the legacy Staphylococcus aureus Protein A and will be the basis of Repligen's future chromatography product development.  Proteins manufactured with recombinant technology have multiple advantages over a natural source such as Staphylococcus aureus including higher quality, product consistency and purity as well as improved supply chain security and a lower cost of production.

"This action by the patent office reflects our continuing investment and commitment to our Bioprocessing business," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "This recently launched recombinant Protein A product is an important step in expanding our business through both organic growth and product acquisition."

Repligen is the world's leading supplier of recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, a highly successful class of biopharmaceutical.  There are currently more than 25 monoclonal antibodies that have received regulatory approval with more than 200 products in various stages of clinical development.  The worldwide revenues from this class of drug exceeded $35 billion in 2009.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.  In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability.  Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453.  Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

SOURCE Repligen Corporation

RELATED LINKS
http://www.repligen.com

'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... CITY, Mo. , May 3, 2016 /PRNewswire/ ... Kansas Medical Center,s Institute for Advancing Medical Innovation ... and commercialize new drugs, diagnostics and medical devices. ... provides BioNovus Innovations with rights to license, develop ... "This partnership represents ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, an ... rheumatic fever, which damaged his heart. He continued enjoying ... by June 2013, Shepherd,s heart was giving out and ... On June 20, 2013, the Mesa, Arizona ... Heart (TAH-t). Like a heart transplant, the SynCardia TAH-t ...
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 05, 2016 , ... Chronic stress can have a silent, yet dangerous, impact ... immune system and increase inflammation, both of which raise the risk of heart attack ... disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to other ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... honored finalists and winners Tuesday evening, May 3, at the 2016 ISE® Central ... , Scott Pettigrew, Vice President and Chief Security Officer of HMS, was selected ...
(Date:5/5/2016)... , ... May 05, 2016 , ... If you don’t ... marks on your skin, you may want to consider a treatment that some have ... Advanced Dermatology P.C. , Microneedling, also known as skin needling, is a ...
(Date:5/5/2016)... Austin, TX (PRWEB) , ... May 05, 2016 , ... ... existence to offer the breakthrough technology of the new PiQo4™ laser, the first 4-wavelenth ... treating more tattoo inks than any other picosecond laser on the market. Jeremy ...
(Date:5/5/2016)... ... 05, 2016 , ... Liposuction specialist Marcia V. Byrd, MD spoke last month ... the Marriot St. Louis Airport Hotel. This year’s conference was titled “Living with Lipedema ... her unique specialization in treating Lipedema. Dr. Byrd is considered one of the leading ...
Breaking Medicine News(10 mins):